Replicor HBV/HDV Compassionate Use Data Published

Replicor’s REP 2139-Mg Shows Promise in Treating Chronic HBV/HDV Infection

A new study published in the Journal of Hepatology details highly encouraging results from Replicor Inc.’s global compassionate access program for REP 2139-Mg, offering potential hope for patients with chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infection.

The compassionate access program, initiated in France with Dr. Marc Bourlière, provided REP 2139-Mg to 33 patients across 16 sites in eight countries. These individuals had previously failed treatment with bulevirtide or lonafarnib and were living with cirrhosis or decompensated cirrhosis – a notably severe stage of liver disease.

Did you know? – Hepatitis D is a rare but severe form of viral hepatitis that only occurs in people already infected with hepatitis B. It accelerates liver damage and increases the risk of cirrhosis.

Significant Findings in a Challenging Patient Population

The data,released on December 7,2025,highlight several key benefits of REP 2139-Mg:

• Exceptional Safety Profile: The treatment demonstrated an excellent safety record in a patient population considered particularly vulnerable.
• Reversal of Liver Dysfunction: Patients experienced a rapid reversal of symptoms associated with decompensation, leading to improved liver function.
• High Cure Rates: The program achieved significant rates of both HDV cure and HBV functional cure.
• viral Elimination: In certain specific cases, HBV and HDV were completely eliminated from the liver after as little as 10 weeks of therapy.

“REP 2139 is a unique bifunctional agent which directly targets HDV replication and subviral particle assembly,” stated Dr. Andrew Vaillant, Chief Scientific Officer of replicor.”These data continue to reaffirm excellent safety and efficacy of REP 2139-Mg, even in patients with decompensated cirrhosis, and set the stage for phase IIA trials in Europe.”

Pro tip: – Decompensated cirrhosis is a life-threatening condition where the liver is severely damaged and unable to function properly, leading to complications like ascites and hepatic encephalopathy.

Addressing a Critical Unmet Medical need

Chronic HBV and HDV infection represent a significant global health challenge. HDV,in particular,is one of the most severe forms of viral hepatitis,frequently enough leading to rapid progression to cirrhosis and liver failure.Current treatment options are limited, and many patients do not respond adequately.

Replicor,a privately held biopharmaceutical company,has been at the forefront of research into a potential cure for HBV and HDV. The company asserts it possesses the most advanced animal and human clinical data in this field. This latest publication builds upon years of research and growth, demonstrating the potential of REP 2139-mg to address this critical unmet medical need.

The positive outcomes from this compassionate access program pave the way for further

Reader question: – What are the next steps for REP 2139-mg, and how long before it might be widely available to patients? Share your thoughts.

Why: Patients with chronic HBV/HDV infections, particularly those with cirrhosis or decompensated cirrhosis who had failed previous treatments, lacked effective options. Replicor aimed to address this critical unmet medical need.

Who: replicor Inc., lead by Chief Scientific Officer Dr.Andrew Vaillant, initiated a compassionate access program with Dr. Marc Bourlière in France. Thirty-three patients from eight countries participated.

What: Replicor’s REP 2139-mg, a bifunctional agent, was tested in a compassionate access program. The study revealed exceptional safety, reversal of liver dysfunction, high cure rates for both HDV and HBV, and viral elimination